Azenta (AZTA) is a provider of life sciences worldwide, enabling therapies to market faster. George Tsilis discusses AZTA as its trading higher after better-than-expected 4Q earnings. He talks about how AZTA announced a $1.5B share-repurchase program. He notes that the company's 4Q revenue came in at $138.00M versus an estimated $133.72M. He then goes over how AZTA works in areas such as drug development, clinical research, and advanced cell therapies. Tune in to find out more about the stock market today.
15 Nov 2022
Market On Close
01 Dec 2022
Next Gen Investing
30 Nov 2022
Market On Close
23 Nov 2022
Market On Close
21 Nov 2022
Market On Close
08 Nov 2022
Next Gen Investing
09 Nov 2022